// App-Quantinova.ai

Abstract 10201 : Efficacy of Mavacamten in Patients with Symptomatic Hypertrophic Cardiomyopathy: Sub-Group Analyses by Background Beta-Blocker Use from the EXPLORER-HCM and MAVA-LTE Studies

Researchers

Presenter

  • Daniel L Jacoby

Principal Investigators

  • Matthew T Wheeler

  • Perry M Elliott

  • Sara Saberi

  • Amy J Sehnert

  • Jay M Edelberg

  • Wanying Li

  • iacopo olivotto

Medical Centers

  • Stanford Univ, Palo Alto, CA

  • MyoKardia, a wholly owned subsidiary of Bristol Myers Squibb, Brisbane, CA

  • Univ College London Hosp, London

  • Yale University School of Medicine, New Haven, CT

  • University of Michigan, Ann Arbor, MI

  • MyoKardia, a wholly owned subsidiary of Bristol Myers Squibb, Brisbane, CA

  • Careggi Hospital, Florence, Italy

Locations

  • United States

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Cardiovascular (CVS)

Disease

  • Hypertrophic cardiomyopathy

Biomarkers

  • N/A

Drug/Treatment

  • MYK 461

Outcome

  • N/A

Study Design

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT03470545

  • NCT03723655

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved